Advertisement

Disclaimer information: LLS is not associated with any other content, and does not endorse any information, product, service, or advertisement, otherwise included within this site.

Issue 1

2021 ASCO Annual Meeting Urvi A. Shah, MD, Myeloma Service,  Memorial Sloan Kettering Cancer Center, New York As illustrated by the presentations at the 2021 ASCO annual meeting, the field of multiple myeloma (MM) is changing rapidly.1 However the jury is still out on whether we are curing a subset of...

Assigning Risk Based on 17p Deletion in Multiple Myeloma – Not as Simple as...

Faith Davies, MBBCh, MD MRCP, MRCPath At first glance, it seems very simple: the presence of a deletion of the short arm of chromosome 17...

Targeting Dependence on the B-cell lymphoma 2 (Bcl-2) Family in Multiple Myeloma

Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD Department of Hematology and Medical Oncology, Emory University School of Medicine, and Winship Cancer Institute,...

T-Cell Redirecting Bispecific Antibodies for the Treatment of Multiple Myeloma

Niels W.C.J. van de Donk, MD, PhD Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands Introduction Multiple myeloma (MM) patients...

Recent Advances in Myeloma Show Promising Results – Are We Curing Patients or Kicking...

2021 ASCO Annual Meeting Urvi A. Shah, MD, Myeloma Service,  Memorial Sloan Kettering Cancer Center, New York As illustrated by the presentations at the 2021 ASCO...
- Advertisement -
- Advertisement -

Trending Stories

HIGHLIGHTS FROM THE LLS PODCAST, THE PHYSICIAN’S ROLE IN TREATING NEWLY DIAGNOSED PATIENTS

For the October 2021 Treating Blood Cancers healthcare professional podcast episode, Dr. Ken Miller sat down with Dr. Joshua Richter to discuss the physician's...

Assigning Risk Based on 17p Deletion in Multiple Myeloma – Not as Simple as...

Faith Davies, MBBCh, MD MRCP, MRCPath At first glance, it seems very simple: the presence of a deletion of the short arm of chromosome 17...

Targeting Dependence on the B-cell lymphoma 2 (Bcl-2) Family in Multiple Myeloma

Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD Department of Hematology and Medical Oncology, Emory University School of Medicine, and Winship Cancer Institute,...

T-Cell Redirecting Bispecific Antibodies for the Treatment of Multiple Myeloma

Niels W.C.J. van de Donk, MD, PhD Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands Introduction Multiple myeloma (MM) patients...

Recent Advances in Myeloma Show Promising Results – Are We Curing Patients or Kicking...

2021 ASCO Annual Meeting Urvi A. Shah, MD, Myeloma Service,  Memorial Sloan Kettering Cancer Center, New York As illustrated by the presentations at the 2021 ASCO...

MYELOMA 101 – PART II

Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Manisha Bhutani, MD, Charlotte, NC Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)...